Current status of radiation therapy for the management of rectal cancer

William G. Rule, Jeffrey Meyer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Neoadjuvant chemoradiation for stage II and III rectal adenocarcinoma patients is delivered on a routine basis. This treatment paradigm, built on decades of clinical study, is continuously evolving. While multiple radiosensitizers have gained a great deal of interest over the past couple of decades, 5-fluorouracil still remains as the standard radiosensitizing agent. Longcourse preoperative chemoradiotherapy is the current standard of care in the Unites States, but short-course hypofractionated preoperative radiotherapy is advocated by some investigators. This review will discuss the current standard of care in the preoperative setting for patients with rectal cancer and will also examine the novel ways in which investigators are modifying this regimen in an effort to improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)331-343
Number of pages13
JournalCritical Reviews in Oncogenesis
Volume17
Issue number4
DOIs
StatePublished - 2012

Fingerprint

Rectal Neoplasms
Radiotherapy
Standard of Care
Research Personnel
Radiation-Sensitizing Agents
Chemoradiotherapy
Fluorouracil
Adenocarcinoma
Therapeutics

Keywords

  • Chemoradiation
  • Radiotherapy
  • Rectal cancer

ASJC Scopus subject areas

  • Cancer Research

Cite this

Current status of radiation therapy for the management of rectal cancer. / Rule, William G.; Meyer, Jeffrey.

In: Critical Reviews in Oncogenesis, Vol. 17, No. 4, 2012, p. 331-343.

Research output: Contribution to journalArticle

Rule, William G. ; Meyer, Jeffrey. / Current status of radiation therapy for the management of rectal cancer. In: Critical Reviews in Oncogenesis. 2012 ; Vol. 17, No. 4. pp. 331-343.
@article{93d3f6a7f24642efb8f5bacffb5204f6,
title = "Current status of radiation therapy for the management of rectal cancer",
abstract = "Neoadjuvant chemoradiation for stage II and III rectal adenocarcinoma patients is delivered on a routine basis. This treatment paradigm, built on decades of clinical study, is continuously evolving. While multiple radiosensitizers have gained a great deal of interest over the past couple of decades, 5-fluorouracil still remains as the standard radiosensitizing agent. Longcourse preoperative chemoradiotherapy is the current standard of care in the Unites States, but short-course hypofractionated preoperative radiotherapy is advocated by some investigators. This review will discuss the current standard of care in the preoperative setting for patients with rectal cancer and will also examine the novel ways in which investigators are modifying this regimen in an effort to improve patient outcomes.",
keywords = "Chemoradiation, Radiotherapy, Rectal cancer",
author = "Rule, {William G.} and Jeffrey Meyer",
year = "2012",
doi = "10.1615/CritRevOncog.v17.i4.30",
language = "English (US)",
volume = "17",
pages = "331--343",
journal = "Critical Reviews in Oncogenesis",
issn = "0893-9675",
publisher = "Begell House Inc.",
number = "4",

}

TY - JOUR

T1 - Current status of radiation therapy for the management of rectal cancer

AU - Rule, William G.

AU - Meyer, Jeffrey

PY - 2012

Y1 - 2012

N2 - Neoadjuvant chemoradiation for stage II and III rectal adenocarcinoma patients is delivered on a routine basis. This treatment paradigm, built on decades of clinical study, is continuously evolving. While multiple radiosensitizers have gained a great deal of interest over the past couple of decades, 5-fluorouracil still remains as the standard radiosensitizing agent. Longcourse preoperative chemoradiotherapy is the current standard of care in the Unites States, but short-course hypofractionated preoperative radiotherapy is advocated by some investigators. This review will discuss the current standard of care in the preoperative setting for patients with rectal cancer and will also examine the novel ways in which investigators are modifying this regimen in an effort to improve patient outcomes.

AB - Neoadjuvant chemoradiation for stage II and III rectal adenocarcinoma patients is delivered on a routine basis. This treatment paradigm, built on decades of clinical study, is continuously evolving. While multiple radiosensitizers have gained a great deal of interest over the past couple of decades, 5-fluorouracil still remains as the standard radiosensitizing agent. Longcourse preoperative chemoradiotherapy is the current standard of care in the Unites States, but short-course hypofractionated preoperative radiotherapy is advocated by some investigators. This review will discuss the current standard of care in the preoperative setting for patients with rectal cancer and will also examine the novel ways in which investigators are modifying this regimen in an effort to improve patient outcomes.

KW - Chemoradiation

KW - Radiotherapy

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=84870331686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870331686&partnerID=8YFLogxK

U2 - 10.1615/CritRevOncog.v17.i4.30

DO - 10.1615/CritRevOncog.v17.i4.30

M3 - Article

C2 - 23176041

AN - SCOPUS:84870331686

VL - 17

SP - 331

EP - 343

JO - Critical Reviews in Oncogenesis

JF - Critical Reviews in Oncogenesis

SN - 0893-9675

IS - 4

ER -